MARKET

OGEN

OGEN

Oragenics
AMEX
0.6565
+0.0115
+1.78%
After Hours: 0.6658 +0.0093 +1.42% 19:20 02/13 EST
OPEN
0.6500
PREV CLOSE
0.6450
HIGH
0.6600
LOW
0.6423
VOLUME
22.23K
TURNOVER
--
52 WEEK HIGH
9.60
52 WEEK LOW
0.6111
MARKET CAP
2.74M
P/E (TTM)
-0.0383
1D
5D
1M
3M
1Y
5Y
1D
Oragenics previews targeted milestones for 2026
TipRanks · 4d ago
Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI
Benzinga · 4d ago
Weekly Report: what happened at OGEN last week (0202-0206)?
Weekly Report · 4d ago
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Barchart · 4d ago
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
TipRanks · 02/03 13:40
Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design
Benzinga · 02/03 13:35
Weekly Report: what happened at OGEN last week (0126-0130)?
Weekly Report · 02/02 09:57
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/28 21:05
More
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

Webull offers Oragenics Inc stock information, including AMEX: OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.